熱門資訊> 正文

ADC Therapeutics第二季度收益预览

2026-08-13 03:06

ADC Therapeutics (ADCT) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open.
The consensus EPS Estimate is -$0.22 (+12.0% Y/Y) and the consensus Revenue Estimate is $18.9M (+0.3% Y/Y).
Over the last 2 years, ADCT has beaten EPS estimates 0% of the time and has beaten revenue estimates 50% of the time.

More on ADC Therapeutics

ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL - Slideshow
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
ADC falls as RBC downgrades on trial data for lymphoma therapy (update)
Seeking Alpha’s Quant Rating on ADC Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。